Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $28 to $31.